Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

VRCA

Verrica Pharmaceuticals Inc

Nov 20 • 12:19PM ET

4.38

-0.10 -2.23 %

Healthcare • Biotechnology • USA • NASD

Peers: DERM HRTX ACRS SUPN CLSD KPTI XERS ADMA DMAC EYPT

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.44	Insider Own	59.64%	Shs Outstand	9.49M	Perf Week	13.18%
Market Cap	41.57M	Forward P/E	-	EPS next Y	-2.08	Insider Trans	0.00%	Shs Float	3.83M	Perf Month	12.02%
Enterprise Value	56.21M	PEG	-	EPS next Q	-0.87	Inst Own	29.45%	Short Float	10.96%	Perf Quarter	-19.85%
Income	-26.01M	P/S	1.35	EPS this Y	93.54%	Inst Trans	6.17%	Short Ratio	1.46	Perf Half Y	-29.35%
Sales	30.83M	P/B	-	EPS next Y	-117.05%	ROA	-70.48%	Short Interest	0.42M	Perf YTD	-37.43%
Book/sh	-1.80	P/C	1.97	EPS next 5Y	58.54%	ROE	-1546.58%	52W High	13.60 -67.79%	Perf Year	-50.69%
Cash/sh	2.22	P/FCF	-	EPS past 3/5Y	-4.45% -5.46%	ROIC	-469.74%	52W Low	3.28 33.54%	Perf 3Y	-80.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-14.25% -	Gross Margin	91.36%	Volatility	10.05% 7.90%	Perf 5Y	-94.93%
Dividend TTM	-	EV/Sales	1.82	EPS Y/Y TTM	81.16%	Oper. Margin	-51.14%	ATR (14)	0.33	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.11	Sales Y/Y TTM	234.73%	Profit Margin	-84.38%	RSI (14)	59.44	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	1.19	EPS Q/Q	99.41%	SMA20	16.99%	Beta	1.53	Target Price	16.33
Payout	-	Debt/Eq	-	Sales Q/Q	905.39%	SMA50	7.08%	Rel Volume	0.31	Prev Close	4.48
Employees	71	LT Debt/Eq	-	Earnings	Nov 14 AMC	SMA200	-20.12%	Avg Volume	287.15K	Price	4.38
IPO	Jun 15, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	92.06% 47.06%	Trades		Volume	40,729	Change	-2.23%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

Nov-17-25 04:00PM	Verrica Pharmaceuticals Inc (VRCA) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com) -5.09%
Nov-14-25 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-10-25 08:00AM	Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +11.85%
Oct-24-25 11:00AM	Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 04:05PM	Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union (GlobeNewswire) +7.95% -9.82%
04:05PM	Loading…
Oct-07-25 04:05PM	Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-19-25 08:00AM	Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH (TO-208) in Japan for the Treatment of Molluscum Contagiosum (GlobeNewswire) +8.66%
Sep-02-25 07:00AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 03:12AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Aug-12-25 05:20PM	Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-11-25 09:42AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.51%
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.20%
07:00AM	Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 (GlobeNewswire)
Jul-09-25 07:00AM	Verrica Pharmaceuticals Reports Strong Growth in YCANTH Dispensed Applicator Units in 2Q 2025 (GlobeNewswire)
07:00AM	Loading…
Jul-01-25 07:00AM	Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire) +13.37%
May-28-25 08:00AM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire) -5.78%
May-14-25 08:10AM	Q1 2025 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ... (GuruFocus.com)
May-13-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.63%
04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +15.07%
09:52AM	Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result (GuruFocus.com)
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.97%
May-07-25 08:00AM	Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 (GlobeNewswire) -9.20%
May-02-25 07:10AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates (Zacks)
Apr-30-25 08:00AM	Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York (GlobeNewswire)
Apr-07-25 08:00AM	Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH Dispensed Applicator Units in First Quarter 2025 (GlobeNewswire) +21.75%
Apr-02-25 04:05PM	Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors (GlobeNewswire)
Apr-01-25 09:55AM	Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:00AM	Loading…
Mar-31-25 08:00AM	Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-25 07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.75%
Mar-12-25 01:48PM	Q4 2024 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.56%
03:08AM	Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com)
Mar-11-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 07:00AM	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 (GlobeNewswire)
Feb-27-25 10:00AM	Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -16.89%
Feb-25-25 04:05PM	Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston (GlobeNewswire)
Jan-21-25 07:00AM	Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference (GlobeNewswire) +5.12%
Dec-20-24 07:00AM	Verrica Provides Business and Operational Update (GlobeNewswire)
Dec-09-24 04:15PM	Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.94% -7.84%
Dec-06-24 08:00AM	Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-21-24 07:30AM	Verrica Announces Pricing of $42.0 Million Public Offering (GlobeNewswire) +11.56%
Nov-20-24 04:05PM	Verrica Announces Proposed Public Offering (GlobeNewswire)
Nov-04-24 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition (GlobeNewswire) -6.54% -44.23%
Oct-24-24 07:00AM	Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-09-24 06:21PM	Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)
Oct-02-24 07:30AM	Verrica Pharmaceuticals Announces Restructuring of Commercial Organization (GlobeNewswire) -18.98%
Sep-29-24 08:02AM	Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:27AM	Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers? (Insider Monkey) -5.68%
Sep-20-24 05:21AM	Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) (Newsfile) -6.70%
Sep-04-24 07:30AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York (GlobeNewswire) +5.50%
Aug-15-24 07:32AM	Verrica stock drops after half patients tumours gone in skin cancer trial (Clinical Trials Arena) -6.73%
Aug-14-24 09:52AM	Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -40.80%
08:55AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma (GlobeNewswire)
Aug-06-24 07:30AM	Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 (GlobeNewswire) -5.45%
Jul-15-24 11:57AM	7 Short-Squeeze Stocks That Could Beat Down the Bears (InvestorPlace)
Jul-01-24 07:30AM	Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. (GlobeNewswire) +9.05%
May-30-24 04:30PM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-15-24 09:11AM	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth (MT Newswires)
07:30AM	Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire)
May-14-24 09:28AM	HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating (MT Newswires)
08:50AM	Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating (MT Newswires)
03:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +19.50%
09:12AM	Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review (GuruFocus.com)
08:40AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Verrica Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-08-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-06-24 06:35AM	Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? (Zacks)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-02-24 07:30AM	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:30AM	Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA (GlobeNewswire) +5.14%
Mar-01-24 09:10AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.31%
Feb-29-24 08:11AM	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com) -7.87%
07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:30AM	Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire) +5.00%
Feb-22-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 07:30AM	Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition (GlobeNewswire) -7.58%
Jan-29-24 07:30AM	Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services (GlobeNewswire)
Jan-22-24 07:44PM	7 Potential Short-Squeeze Stocks Poised for Rapid Gains (InvestorPlace)
Jan-05-24 07:30AM	Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Jan-04-24 07:30AM	Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH for the Treatment of Common Warts (GlobeNewswire)
Jan-03-24 07:30AM	Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH (GlobeNewswire)
Dec-15-23 01:49PM	Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today? (InvestorPlace) +61.97%
06:00AM	Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-11-23 10:13AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 08:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-09-23 07:30AM	Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire) -9.83%
Oct-25-23 07:00AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 (GlobeNewswire)
Sep-27-23 08:00AM	Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023 (GlobeNewswire)
Aug-31-23 08:00AM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 08:30AM	Verrica Pharmaceuticals Announces First Sale of YCANTH to FFF Enterprises (GlobeNewswire)
Aug-23-23 07:30AM	Verrica Issues Statement in Support of FDAs Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum (GlobeNewswire)
Aug-10-23 04:05PM	Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Aug-08-23 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hayes Christopher G.	CHIEF LEGAL OFFICER	Mar 17 '25	Sale	0.65	4,315	2,805	176,458	Mar 18 06:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

VRCA

Verrica Pharmaceuticals Inc

Upgrade your FINVIZ experience